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ABSTRACT
Introduction: Effective communication between
patients and healthcare professionals (HCPs) is
important to enhance outcomes in multiple scle-
rosis (MS). However, in practice, patients often
report a disconnect in communication. Commu-
nication tools to aid patient–HCP communication
have a long history of use in many chronic condi-
tions. For example, symptom diaries have been
shown to enhance outcomes in cancer, headache
and sleep disorder management. MS in the 21st
Century, a Steering Group of HCP specialists and
patients with MS (PwMS), has created two com-
munication tools designed for use by both patients
and their HCPs.
Methods: The Steering Group first identified
prominent issues in patient–HCP communica-
tion through group discussions and survey data.
Following this, a series of workshops led to the
development of two communication tools as
potential solutions to these identified issues in
communication.
Results: The two most prominent issues iden-
tified were HCP time constraints during
appointments and the misalignment of patient
and HCP priorities—the communication tools
developed through the workshops were created
to address these. The ‘‘myMS priorities’’ tool [see
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supplementary materials] is designed to maxi-
mize the use of consultation time while the
‘‘myMS commitments’’ tool [see supplementary
materials] aims to improve patient–HCP shared
decision-making.
Conclusions: The MS in the 21st Century
Steering Group adopted a broad, iterative and
collaborative approach in the development of
these tools to help ensure they would be as
useful as possible to both HCPs and PwMS.
These tools have been developed through
shared patient–HCP expertise and are based on
existing tools in other therapy areas as well as a
review of the existing literature and data from
MS in the 21st Century Steering Group surveys.
The next steps will focus on the validation of
these tools through testing them in real-world
environments and clinical trials.
Funding: Merck KGaA, Darmstadt, Germany.
Keywords: Communication tools; Shared
decision-making; MS care; Neurology
INTRODUCTION
There has been significant success in the man-
agement of multiple sclerosis (MS) over the last
25 years [1]. Yet, despite these advances, patient
outcomes in MS remain suboptimal. Reasons for
this include variations in the standard of care as
well as in patient satisfaction, engagement and
adherence [2–5].
Patient adherence is an important factor in MS
management [4–6], but can be compromised by
poor satisfaction with therapy, perceived lack of
efficacy, and the occurrence of side effects and
tolerability issues [7, 8]. Good patient–healthcare
professional (HCP) communication plays a key
role in improving treatment satisfaction and
treatment adherence [7, 9, 10]. HCPs have a
responsibility to encourage good communication
and to provide education, thereby enhancing
adherence and addressing low expectations in the
management of MS [11–13].
Despite the known benefits of good
patient–HCP communication, there are still sig-
nificant communication barriers between both
parties [3, 10]. The HCP and patient can have
different perceptions of the patient’s care priori-
ties [3, 9, 14]. Some patients report unmet needs
regarding the amount and quality of information
they receive from their HCPs during consulta-
tions [15]. HCPs also often misjudge patient dis-
comfort regarding discussion of topics such as
tremors and walking abilities, as well as sensitive
topics that might be considered private, such as
bladder control or sexual difficulties [9, 14].
Worryingly, nearly a fifth of patients report feel-
ing uncomfortable about discussing their symp-
toms with their HCP, specifically neurologists [9].
Some patients felt that their HCP often adopted a
‘‘one-size-fits-all’’ approach, whereas they would
prefer a more personalized discussion about their
care [3]. For example, some patients with MS
(PwMS) felt important personal aspects such as
their changing practical needs due to disease
progression, as well as their social care and
employment issues, were not fully addressed by
their HCP during consultations [3].
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Shared decision-making has been described to
be at the heart of patient-centered care [15] and is
increasingly recognized as best practice [9, 16].
Although it is not suited to all patients, this
model, which involves patients making informed
decisions regarding their care in partnership with
their HCP, has been shown to improve overall
patient satisfaction and treatment adherence in
MS [9, 15, 16]. Increased shared decision-making,
including better patient education may improve
disease management [15–17].
Shared decision-making requires good com-
munication between the patient and the HCP
[9, 16]. HCPs should adopt a collaborative
approach when working with patients, listening
to their needs and informing them about the
available treatment options [18]. However, in
practice, many PwMS often report a lack of
objective information and of difficulties making
an informed choice [10]. Moreover, surveys of
PwMS have found that many patients feel that
they have little input into their treatment deci-
sions [9, 12]. Short consultation times may be one
factor contributing to poor patient–HCP com-
munication [19]; many PwMS may feel that they
do not get enough contact time with their neu-
rologist [12, 19]. Some patients have also reported
a perceived reluctance of HCPs to prescribe cer-
tain medications. HCPs, conversely, cited an
inability to prescribe certain medications due to
cost restrictions [3]. Disconnects in communica-
tion such as these need to be addressed if patient
outcomes in MS are to be optimized.
Issues around patient–HCP communication
are of particular importance to members of the
‘‘MS in the 21st Century’’ initiative. MS in the 21st
Century is led by a Steering Group of 15 MS
specialists and 12 patient advocates from 15
countries. Members of this unique initiative col-
laborate to identify and overcome gaps in
patient–HCP communication, and have pub-
lished eight key actions to help bridge commu-
nication gaps within MS treatment and improve
the standard of patient-centered care [3]. The
Steering Group has a strong commitment to
equality of input and mutual respect among
members and explicitly adopts a collaborative
and inclusive stance in their work [20].
In considering ways to further improve
patient–HCP communication, MS in the 21st
Century has created two communication tools:
‘‘myMS Priorities’’ (see supplementary materials)
and ‘‘myMS Commitments’’ (see supplementary
materials). These tools and the process of their
development are described below.
METHODOLOGY
The development process of the communica-
tion tools introduced in this paper took place
over a series of HCP–patient joint and separate
workshops as part of the activities at the Steer-
ing Group’s regular planning meetings. These
workshops first identified areas of disagreement
in the perceptions of patient and HCP priorities
through group discussions and survey data.
Following the identification of these gaps in
communication, the workshops developed
potential solutions to help align patient–HCP
perceptions and priorities coming up with the
concept of the ‘‘myMS priorities’’ pre-consulta-
tion checklist and the ‘‘myMS commitments’’
disease management contract. As the last step,
the content and format of these communica-
tion tools were presented by members of the
Steering Group to audiences at international
congresses for feedback and validation. In total,
5 workshops were held between March 2016
and July 2017 (Table 1).
Summary of Workshops
Compliance with Ethics Guidelines
This publication does not contain any clinical
studies with human participants or animals
performed by any of the authors. All survey
responses were undertaken on a voluntary basis
with acceptance of terms outlining the use of
the data. All responses were received and ana-
lyzed in an aggregated and anonymous format.
RESULTS
Workshop 1
The groups identified many similar themes
during the separate HCP and PwMS workshops;
however, there were key differences in how the
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Table 1 Stages of the MS in the 21st Century communication tool development process
Workshop details Attendees Objectives
Workshop 1: 22–23 March, 2016, Frankfurt,
Germany. Parallel HCP and PwMS workshops
followed by joint-discussion workshop
11 HCPs
11 PwMS
To review answers to the following three questions:
What are the greatest areas of unmet need in MS
care?
What are the most important recent successes in MS
care?
What deﬁnes or contributes to the concept of
treatment burden in MS care?
HCP–patient unmet needs survey (see supplementary
materials): After the workshop, MS in the 21st
Century developed a survey to further explore
differences in the HCP and patient responses. The
survey consisted of 10 questions and was run at a
series of internal neurology congresses and patient
meetings throughout 2016–2018. Respondents
typically were highly educated pwMS and
neurologists. (Appendix 3)
Workshop 2: 13 July, 2016, Amsterdam, the
Netherlands. PwMS only workshop chaired by
HCP member of Steering Group
12 PwMS To further discuss and explore the PwMS perspective
on the outputs of the Frankfurt workshops and how
differences could be addressed
To develop potential solutions to areas of unmet need
for PwMS
To consider how these solutions might also beneﬁt
HCPs
Workshop 3: 14 September, 2016, London, UK. Joint
PwMS–-HCP workshop
10 HCPs
10 PwMS
For the HCP members of the Steering Group to input
on the recommendations from the Amsterdam
workshop and how HCP perspectives could be
addressed
For the joint Steering Group to align on the goals of
the proposed communication tools
For the joint Steering Group to begin developing the
outline of the tools
Workshop 4: 8–9 February, 2017, Barcelona, Spain.
Parallel HCP and PwMS workshops followed by
joint-discussion workshop
7 HCPs
8 PwMS
To consider whether the content of the
communication tools could be made more patient-
friendly
To consider how the tools would be used by PwMS
and HCPs in a real-world setting and to decide on a
format to support this use
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Table 2 Comparison of patient and HCP Steering Group perspectives on contemporary issues in MS care
Discussion topic Patients HCPs
Greatest area of unmet need Monitoring of ‘‘invisible’’ symptoms and
mental wellbeing
Access to HCPs
Improve HCP education
Holistic approach to treatment
Personalized care and treatment options
Appropriate patient education/information
Improved public awareness of MS
Symptom-free disease and
ultimately a cure
Continuity and quality of
care
Reimbursement and
accessibility of treatment
Neuroprotective and
personalized treatments
Better treatment for
progressive MS
Patient engagement and
advocacy
Most important recent successes in MS Increased patient support from healthcare
team
Treatment options and diversity of treatment
More focus on quality of life
Globalized online community
Increased focus on progressive MS
Hope for MS patients from treatment,
support, research etc.
Increased treatment options
Improved multidisciplinary
care
Better quality interventions
Enhanced collaboration
between stakeholders
Advances in research
What deﬁnes or contributes to the concept
of treatment burden?
Risk–beneﬁt balance of treatment
Treatment access
Lack of time with the HCP
Irregular review and monitoring
Geographical differences contribute to
inequality in treatment options
Compliance and adherence
Pharmacovigilance
Side effects
Cost
Inadequate support
Risk–beneﬁt balance of
treatment
Uncertain future
Table 1 continued
Workshop details Attendees Objectives
Workshop 5: 5 July, 2017, Windsor, UK. Joint
PwMS–HCP workshop
8 HCPs
7 PwMS
To ﬁnalize the content and format of the
communication tools
To develop a joint educational workshop concept for
the presentation of the tools at international
congresses
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two groups prioritized the areas of unmet need
in MS care (Table 2). Of particular interest were
the key priorities ‘‘monitoring of invisible
symptoms and mental wellbeing’’ and ‘‘im-
proving HCP education’’ which were identified
by the PwMS but not by the HCP group.
Survey
In total, the ‘‘unmet needs’’ survey (Fig. 1) col-
lected responses from 296 HCPs and 143 PwMS.
Of particular interest were the responses to the
question ‘‘What are the biggest barriers to
effective communication between HCPs and
PwMS?’’ The majority of PwMS (68%) and a
large proportion of HCPs (44.5%) noted ‘‘lack of
time in appointments’’ as being the biggest
barrier to effective communication.
All survey responses were undertaken on a
voluntary basis with acceptance of terms out-
lining the use of the data. All responses were
received and analyzed in an aggregated and
anonymous format.
Workshop 2
It was agreed during this workshop that a ‘‘one-
size-fits-all’’ solution to any of unmet needs
identified (Table 2) would not be possible based
on the individual and unique needs of PwMS.
The members therefore decided that the key
objective of any MS in the 21st Century activity
should be to increase the ability of the HCP to
provide, and PwMS to receive, personalized
care. Recognizing that the ability of the HCP to
provide personalized care is dependent on
understanding the needs of the patient; and
that there are multiple disconnects in the
perceptions of HCPs and PwMS (as highlighted
by their previous work), the Steering Group
members brainstormed a communication tool
that could align PwMS and HCP perspectives.
They proposed the concept of having a
‘‘checklist’’ that would enable PwMS to record
their priorities and concerns and then bring this
document along to their appointment. The group
envisaged that this checklist would also allow
PwMS to track and record their symptoms, cap-
ture their disease history, and stimulate discus-
sions to cover the symptoms that affect them
most, including invisible symptoms that might
otherwise be ignored. In addition, they discussed
the importance of balancing communication
between the patient and HCP in appointments,
stressing that the checklist should also allow
HCPs to identify their priorities for care.
The group acknowledged that the value of
this communication tool was heavily depen-
dent on the level of trust within the
patient–HCP relationship. HCPs need to trust
that their patients will be honest and open
when using the tool and, in turn, PwMS need to
trust that their HCP will listen to their per-
spective and tailor their care accordingly. The
group therefore devised the concept of a disease
management ‘‘contract’’ between PwMS and the
HCP outlining a mutual understanding of each
other’s responsibilities within the relationship
and providing a foundation for balanced con-
versations and realistic treatment expectations.
Workshop 3
It was decided that, to maximize the potential
of the checklist, it is essential that PwMS share
the completed version with their HCP in
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permitted)
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advance of the consultation. This ensures that
the HCP has sufficient time to consider their
patient’s priorities and plan accordingly. For
example, sending the checklist beforehand, on
the morning of the consultation, could enable
both parties to make the best use of the limited
time available during the consultation and to
ensure that all priorities are sufficiently
addressed.
It was also decided that it was vital for the
disease management contract to be framed as
an agreement between equal partners in MS
management, and for it not to get interpreted as
a binding adherence contract. By the end of the
workshop, the joint Steering Group members
had agreed upon and defined the objectives of
each of the communication tools (Table 3) and
begun developing the content of both tools.
Workshop 4
The Steering Group decided that, in order to
best achieve its objectives, the checklist should
not be a ‘‘tick box’’ of provided options but,
instead, have an open structure allowing both
parties to record their priorities in their own
words. The Steering Group named this pre-
consultation checklist tool ‘‘myMS priorities’’ in
order to accurately reflect this content and goal.
In view of the other objectives of the ‘‘myMS
priorities’’ tool, the Steering Group added
specific sections covering changes to symptoms,
medication and lifestyle. A section allowing
PwMS to record changes to their symptoms
since their last appointment was also included
with the aim of providing PwMS a way for them
to raise potentially sensitive topics such as sex-
ual function and relationship questions as well
as ensuring that invisible symptoms are suffi-
ciently recognized and addressed by their HCP
(Table 4).
To support shared decision-making, a section
that allows PwMS to share information about
their current treatment experience including
non-prescription therapies and other prescrip-
tion medications was added. Also, to support
PwMS empowerment and self-management, a
section was included allowing PwMS to record
changes to their lifestyle and any feelings
regarding how this affected their health.
Finally, recognizing the importance of PwMS
support networks, a section was added to allow
partners, family members, friends, or caregivers
to note any questions they might have for the
HCP.
In developing the second tool, the Steering
Group members re-iterated that this tool was
needed to underpin the open and honest com-
munication between HCPs and PwMS that was
considered essential for the effective use of the
pre-consultation checklist-based, ‘‘myMS prior-
ities’’ tool. They again highlighted the impor-
tance of emphasizing that the tool is not
intended to be a contract or mandatory docu-
ment, but rather an opportunity for the patient
to participate in improving their own care.
Table 3 Objectives of the two communication tools as
deﬁned by the Steering Group during Workshop 3
Pre-consultation checklist Disease management
contract
To ensure that the patient’s
priorities and concerns
are openly acknowledged
by their doctor
To help MS patients and
their doctors to share
information and disease
management
responsibilities
To provide an opportunity
for HCPs to also identify
their priorities for the
consultation
To improve self-
management and
treatment adherence of
patients
To ensure that all
symptoms, concerns and
feelings (positive and
negative) are recorded
and provided to an HCP
ahead of appointments
To facilitate greater trust in
the patient–HCP
relationship
To share information that
may affect management
decisions
To encourage conﬁdent,
open interaction between
both parties
To make the best use of the
time available during a
consultation
To encourage greater levels
of openness between
patients and their support
network
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Considering these aspects, as well as the overall
objectives of the tool, the group decided to call
this disease management agreement-based tool
‘‘myMS commitments’’.
The PwMS and HCP Steering Group mem-
bers discussed the responsibilities that they
would expect from each other in order to
maximize the efficacy of the tool in MS care.
These responsibilities were then included in the
statements of ‘‘commitment’’ for both the
PwMS and the healthcare team and grouped
into common themes. The four themes inclu-
ded in the final version of the ‘‘myMS commit-
ments’’ tool are ‘‘understanding and learning
about MS’’, ‘‘how to get the best from appoint-
ments’’, ‘‘MS treatment and management’’, and
‘‘how to get the best out of life’’.
Workshop 5
At the final workshop, the Steering Group con-
sidered how the tools should be presented and
used. It was felt important that users should
have the choice between both physical and
digital copies of the tools as these have different
but complementary benefits. Digital versions of
the tools make it easy for the PwMS to refer to
the tool throughout the year. They also simplify
the sharing process between the PwMS and HCP
and remove the risk of the tool being lost or not
brought to the appointment. However, it was
felt that many PwMS may prefer to use paper
versions of the tools for reasons such as ease of
use during appointments and in order to
involve a family member, friend, or carer in the
process of using the tool, both of which might
be particularly important for patients with
cognitive impairment.
In order to gather feedback on the tools,
including any possible limitations, the Steering
Group developed a workshop format for use at
international neurology congresses and PwMS
meetings. The workshop series titled ‘‘Two
monologues do not make a dialogue’’ used
roleplay videos developed by the Steering
Group to highlight common issues encountered
by both PwMS and HCPs during appointments
and how the ‘‘myMS priorities’’ and ‘‘myMS
commitments’’ tools could enhance these
interactions. These workshops were run at three
international congresses and one patient
conference.1
The feedback from this workshop series
came from both HCPs and PwMS. For HCPs,
possible limitations identified included time
constraints which could prevent pre-appoint-
ment preparation and the possible loss of tool
copies, especially when in transit to the HCP.
Possible limitations for PwMS included their
opinion that the tool is unnecessary, priorities
changing before appointments, and, impor-
tantly, any cognitive or physical difficulties
which could impair their ability to complete
the forms.
Table 4 Topics included in the symptoms tracker section
of the my MS priorities tool
Moving and walking
Stiffness and spasms
Balance and dizziness
Pain and sensation
Vision
Speech
Hearing
Bladder and bowel
Fatigue and sleep
Moods and emotions
Concentration and memory
Relationships and sexual function
Infections
Other concerns
1 The ‘‘Two monologues do not make a dialogue’’
workshops were conducted at international congresses
ECTRIMS 2017, ECF 2017, CMSC 2018 and a Merck
Patient Ambassador Summit 2018.
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myMS PRIORITIES (PRE-
CONSULTATION CHECKLIST-
BASED TOOL)
The priorities tool enables PwMS to record
their personal priorities for each appoint-
ment in a dedicated section which can be
shared with the doctor, MS nurse or other
members of the healthcare team in advance
(‘‘tear off’’ section can be sent ahead of
appointment).
Benefits for the Patient
The tool allows PwMS to structure their
questions and concerns, and to come to
each appointment fully prepared. It also
prompts recollection of changes since the
last appointment and offers the opportunity
to raise difficult or sensitive issues (e.g.,
relationships, sexual health, employment)
which may not be as high on the HCP’s list
of priorities. If patients feel they are being
listened to and that their doctor and MS
nurse are focusing on their needs, they will
feel greater satisfaction regarding their care.
Benefits for the HCP
Receipt of patient priorities ahead of
appointments allows the HCP and health-
care team to gain important insight into the
issues that are of the highest priority to the
PwMS, ensures effective use of consultation
time and offers the opportunity to prepare
and plan referrals ahead of time. Healthcare
team priorities for each appointment can
also be shared for the PwMS to consider.
myMS COMMITMENTS
(DISEASE MANAGEMENT
AGREEMENT-BASED TOOL)
The commitments tool is an ‘‘agreement
document’’ that outlines the ways in which
PwMS and HCPs can each take responsibility
in the management of MS. It offers the
PwMS and their HCP the chance to agree
and commit, in a non-binding way, to their
respective responsibilities.
Benefits for the Patient
Identifying the aspects of care where PwMS
can have agency over their management can
increase patient feelings of empowerment.
This in turn supports a more open and
honest relationship with the healthcare
team and instils and builds confidence in
patients to discuss their disease
management.
Benefits for the HCP
The tool also outlines a realistic idea of what
PwMS can expect from their healthcare
team, and what the healthcare team can in
turn expect from them, increasing trust and
encouraging more holistic and personalized
care. Increased patient engagement leads to
better adherence to management and treat-
ment, while shared responsibility for patient
education reduces the risks of patients
turning to unverified sources of information
online.
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DISCUSSION
Chronic conditions such as MS for which
patients require lifelong treatment, and for
which multiple treatment options of similar
efficacy exist, may strongly benefit from a good
patient–HCP relationship which facilitates
shared decision-making [9, 15, 16]. A number of
communication tools exist for chronic condi-
tions, including MS, and have been associated
with improved outcomes such as increased
patient satisfaction and knowledge [21–23]. In
order to improve patient–HCP communication,
MS in the 21st Century has developed two
communication tools, the pre-consultation
checklist-based, ‘‘myMS priorities’’ and the dis-
ease management agreement-based, ‘‘myMS
commitments’’.
The MS in the 21st Century Steering Group
adopted a broad, iterative and collaborative
approach in the development of these tools to
help ensure that they would be as useful as
possible to both HCPs and PwMS. These tools
have been developed through shared
patient–HCP expertise and are based on existing
tools in other therapy areas, as well as a review
of the existing literature and data from MS in
the 21st Century Steering Group surveys. Both
the literature review and survey data identified
lack of HCP time in appointments [12] and
misalignment of patient and HCP priorities in
MS care as prominent gaps in patient–HCP
communication [3, 9].
A series of meetings were held with clear
objectives to outline the development and
content finalization of the tools. The workshops
and sessions were also set up to encourage as
much HCP–patient interaction and collabora-
tion as possible. Further, the inclusion of
multinational participants aimed to make the
tools applicable to the largest population pos-
sible. The fact that the tools are not linked to
any specific MS treatment means that they can
be used by all patients, regardless of their dis-
ease status. The tools are currently available in
six languages (English, French, German, Span-
ish, Italian, Romanian) to increase accessibility.
The final step in the development of these tools
focused on gaining feedback from a wider
audience through workshops, specifically at
three international congresses.
Existing communication tools which the MS
in the 21st Century Steering Group considered
when creating ‘‘myMS priorities’’ and ‘‘myMS
commitments’’ included patient–physician
contracts, symptom diaries and checklists. The
patient–HCP contract has been used in fields
such as diabetes, hypertension, weight control
and opioid addiction management [23–26].
Contracts are agreements between the patient
and HCP detailing the responsibilities of both
parties toward the patient’s care. Studies have
shown contracts to increase patient adherence
in various patient populations [23, 24]. How-
ever, many different types of contracts exist
and, while there is documented efficacy for
some types of contract, other types have shown
limited efficacy at best [27].
The patient–provider agreement is an exam-
ple of a contract used in opioid addiction
treatment for which studies have demonstrated
only weak efficacy. These contracts often
include a section describing the ‘‘consequences’’
(to the patient) of non-compliance with the
agreement [28]. When reviewing such con-
tracts, Bachman and Ho [29] identified that ‘‘if
patients distrust their HCP, or feel distrusted by
them, this may destabilize the therapeutic
relationship and compromise care’’. Colleen
[30] also echoed this view, citing that opioid
contracts lacked efficacy and diminished
patients trust while also mentioning ‘‘patient’s
trust improves adherence to treatment’’.
The diabetes responsibility contract is
another type of contract used in clinical prac-
tice. This type of agreement focuses on patient
empowerment and may increase treatment
adherence [31, 32]. In contrast to ‘‘conse-
quences’’ for non-compliance of the patient to
opioid agreements, many diabetes responsibil-
ity contracts provide positive reinforcement for
patients when they fulfil their agreed commit-
ments [32].
When creating the ‘‘myMS Commitments’’
tool, MS in the 21st Century Steering Group
members were acutely aware that contracts,
while proven to be beneficial, could do more
harm than good if not created properly. This is
due to the inherent power imbalance that exists
Adv Ther (2019) 36:3238–3252 3247
in patient–HCP relationships [25]. In attempt-
ing to address this imbalance, the group based
this contract on shared decision-making and
promoting patient empowerment, factors
known to increase patient satisfaction and
treatment adherence [9, 33].
When creating the ‘‘myMS Priorities’’ tool,
the MS in the 21st Century Steering Group
wanted to combine selected benefits of symp-
tom diaries and checklists into a new, single
tool. Symptom diaries can improve treatment
adherence, and both patients and HCPs have
shown their willingness to use them. These
diaries are traditionally used to help patients
record their symptoms—and in some cases their
effect on the patient—accurately. Without a
diary, the patient would need to rely purely on
their memory to recall symptoms at their next
consultation with their HCP, which could be
imprecise especially when there is a long period
of time between consultations [34]. This is par-
ticularly relevant in MS where as many as
40–65% of patients may have some form of
cognitive impairment [35]. The patient can
complete ‘‘myMS Priorities’’ at home with help
from their family or caregiver, which again may
be particularly relevant for PwMS who have
cognitive impairment.
Unlike existing symptom diaries in MS such
as the MS symptom and impact diary [36],
which are tools which record symptoms as a
measure of the impact of MS on the patient, the
‘‘myMS Priorities’’ tool aims to help patients and
HCPs start conversations about potentially
embarrassing or invisible symptoms. Recording
their sensitive symptoms in ‘‘myMS Priorities’’
allows patients to raise such symptoms with
their HCP via the tool rather than relying on the
HCP to ask the patient about them.
Checklists can help guide the patient and
HCP through a consultation and ensure that all
relevant topics and needed actions are covered
[37, 38]. For example, a ‘‘What to ask your
doctor’’ patient appointment guide developed
by the NHS lists some suggested questions for
consultations [39]. The MS in the 21st Century
Steering Group saw the value in the patient
listing their priorities, much as they would
appear in checklists, to guide and cover topics
quickly during a time-limited patient–HCP
consultation. They also noted that, unlike
checklists, patient diary responses were open-
ended as opposed to a tick in the box, thereby
allowing the patient to express their priorities in
more detail and guide discussions. Conse-
quently, the ‘‘myMS Priorities’’ tool allows
patients to list priorities much in the style of a
checklist but also describe their priorities in a
similar way to describing symptoms in a symp-
tom diary. The availability of both tools in
paper or electronic versions offers patients and
physicians the option to choose their preferred
format based on factors such as convenience
and ease of completion.
As with many communication tools, the
limitations of ‘‘myMS Commitments’’ and
‘‘myMS Priorities’’ relate to commitment to
their use by patients and HCPs. Possible limi-
tations of the tools, including that gathered
from feedback in international congresses, are
that the HCP may not always have the time in
clinical practice to optimally use the tools, and
that patients may sometimes not have the will
or ability to use them. Another limitation is
that, while a diverse range of participants were
used in the development of the tool, additional
responses from patient caregivers and the fam-
ilies of PwMS could have been beneficial.
Finally, patients who are more engaged with
their MS care, such as those who research and
probatively manage their condition, may be
more likely and open to use these tools than
patients who take a less active approach to their
management. In addition, the data gathered to
support the development of these tools were
likely predominately from more highly engaged
and educated PwMS. While this could lead to a
bias in the survey responses, the group would
hypothesize that the communication gap
between HCPs and PwMS in a standard clinical
setting is therefore in fact far greater than has
been identified in the data collected here.
To the authors’ knowledge, no communica-
tion tools such as ‘‘myMS priorities’’ and ‘‘myMS
commitments’’ currently exist for PwMS. While
remote and digital tools for PwMS are available,
they are not specifically aimed at the doc-
tor–patient relationship in the form of a ‘‘con-
tract’’ or to minimize disparities in treatment
perceptions [40]. Nor do such tools have the
3248 Adv Ther (2019) 36:3238–3252
same basis in research for their development as
that for ‘‘myMS priorities’’ and ‘‘myMS
commitments’’.
CONCLUSIONS
Development of the pre-consultation checklist-
based ‘‘myMS priorities’’ and disease manage-
ment agreement-based ‘‘myMS commitments’’
tools has followed a thorough and systematic
approach. The MS in the 21st Century Steering
Group has identified two areas in MS care which
are most in need of improvement, and has tar-
geted them with two new communication tools
which have evolved through incorporating and
combining some features of existing commu-
nication tools.
Thus, ‘‘myMS priorities’’ and ‘‘myMS com-
mitments’’ offer an opportunity to engage and
empower patients in their MS care through a
strengthened patient–HCP relationship. This
could therefore meaningfully improve out-
comes in MS. The next steps will focus on the
validation of these tools through testing them
in real-world environments. These data will be
assessed for improvements in communication
and shared decision-making and to see if this is
reflected by improved patient and HCP reported
outcomes.
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